BioSpace News Archive

Cellectis is currently working with the investigators and clinical sites to obtain IRB’s approval on the revised protocols and resume patient enrollment.

announced today that the company is scheduled to present an update on the company’s programs and progress at several upcoming scientific conferences: Society for Immunotherapy of Cancer 32nd Annual Meeting, Society for Neuro Oncology 22nd Annual Meeting and American Society of Hematology 59th Annual Meeting.

This Note was retired exclusively through a one-time conversion exercised by GS Capital on November 2, 2017 for 83,597,839 shares of the Company’s common stock.

Sectra is launching vendor-neutral access to machine learning in its enterprise imaging platform.

The BlueCielo acquisition is the latest in a series of strategic acquisitions fueling Accruent’s growth.

Revenue for the three months ended September 30, 2017 increased 126% to $17.2 million compared to $7.6 million in the year-ago third quarter.

Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology.

He is world-renown for his work in dermoscopy and confocal microscopy.

ICON announced that it has contributed to a complex pan-European traumatic brain injury (TBI) research study involving over 4,500 patients in 65 sites in 20 European countries.

QIAGEN N.V. announced results of operations for the third quarter and first nine months of 2017, delivering on goals for improvements in adjusted net sales and adjusted earnings.